BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials

References

• Grob JJ, Amonkar MM, Karaszewska B, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a Phase 3, open-label, randomised trial. Lancet Oncol. 2015 Oct;16(13):1389–1398. PubMed PMID: 26433819.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Amonkar MM, Martin-Algarra S, et al. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. Ann Oncol. 2014 Jul;25(7):1428–1436. PubMed PMID: 24769640.
   PubMed Web of Science ®Google Scholar
• Sakaizawa K, Ashida A, Uchiyama A, et al. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. J Dermatol Sci. 2015 Oct;80(1):33–37. PubMed PMID: 26282084.
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002 Jun 27;417(6892):949–954. PubMed PMID: 12068308.
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28:1631–1639, PubMed PMID: 28475671
   PubMed Web of Science ®Google Scholar
• Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016 Sep;17(9):1248–1260. PubMed PMID: 27480103.
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014 Mar;15(3):323–332. PubMed PMID: 24508103.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012 Jul 28;380(9839):358–365. PubMed PMID: 22735384.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017 Oct 5;377(14):1345–1356. PubMed PMID: 28889792.
   PubMed Web of Science ®Google Scholar
• Long GV, Hauschild A, Santinami M, et al. adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017 Nov 9;377(19):1813–1823. PubMed PMID: 28891408.
   PubMed Web of Science ®Google Scholar
• Copley-Merriman C, Stevinson K, Liu FX, et al. Direct costs associated with adverse events of systemic therapies for advanced melanoma: systematic literature review. Medicine (Baltimore). 2018 Aug;97(31):e11736. PubMed PMID: 30075584.
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: A phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018 Apr 20;36(12):1232–1239. PubMed PMID: 29528792.
   PubMed Web of Science ®Google Scholar
• Zhang C, Spevak W, Zhang Y, et al. RAF inhibitors that evade paradoxical MAPK pathway activation. Nature. 2015 Oct 22;526(7574):583–586. PubMed PMID:26466569.
   PubMed Web of Science ®Google Scholar
• Furudate S, Fujimura T, Kambayashi Y, et al. Keratoacanthoma, palmoplantar keratoderma developing from an advanced melanoma patient treated with vemurafenib regressed by the blockade of MEK signaling. J Dermatol. 2017;44:E226–E227, PubMed PMID: 28439948
   PubMed Web of Science ®Google Scholar
• Fujimura T, Kambayashi Y, Tanita K, et al. Two cases of Vogt-Koyanagi Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol. 2018 Jun;45(6):735–737. PubMed PMID: 29488243.
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Juneja VR, Sage PT, et al. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014 Jul;2(7):643–654. PubMed PMID: 24903021.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Moreno HB, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18;7(279):279ra41. PubMed PMID: 25787767.
   PubMed Web of Science ®Google Scholar
• Hajek E, Krebs F, Bent R, et al. BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells. Oncotarget. 2018 Jun 19;9(47):28294–28308. PubMed PMID: 29983861.
   PubMedGoogle Scholar
• Homet Moreno B, Mok S, Comin-Anduix B, et al. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. Oncoimmunology. 2015 Aug 17;5(7):E1052212. PubMed PMID: 27622011.
   PubMed Web of Science ®Google Scholar
• Wang L,L, de Oliveira R, Huijberts S, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell. 2018 May 31;173(6):1413–1425. PubMed PMID: 29754815.
   PubMed Web of Science ®Google Scholar
• Heijkants R, Willekens K, Schoonderwoerd M, et al. Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma. Oncotarget. 2017 Dec 15;9(5):6174–6187. PubMed PMID: 29464063.
   PubMedGoogle Scholar
• Gallagher SJ, Gunatilake D, Beaumont KA, et al. HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. Int J Cancer. 2018 May 1;142(9):1926–1937. PubMed PMID: 29210065.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 Feb;19(2):181–193. PubMed PMID: 29361468.
   PubMed Web of Science ®Google Scholar
• Amin A, Lawson DH, Salama AK, et al. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 4.44. PubMed PMID: 27532019.
   Web of Science ®Google Scholar
• Delord JP, Robert C, Nyakas M, et al. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res. 2017 Sep 15;23(18):5339–5348. PubMed PMID: 28611198.
   PubMed Web of Science ®Google Scholar
• Chisholm JC, Suvada J, Dunkel IJ, et al. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma. Pediatr Blood Cancer. 2018 May;65(5):e26947. PubMed PMID: 29350463.
   PubMed Web of Science ®Google Scholar
• Zakharia Y, Monga V, Swami U, et al. Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study. Oncotarget. 2017 Sep 26;8(51):89182–89193. PubMed PMID: 29179510.
   PubMedGoogle Scholar
• Yam C, Xu X, Davies MA, et al. A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600-mutant solid tumors. Clin Cancer Res. 2018 Jan 1;24(1):22–32. PubMed PMID: 29051322.
   PubMed Web of Science ®Google Scholar
• Saleh MH, Wang L, Goldberg MS. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother. 2016 Jul;65(7):787–796. PubMed PMID: 26646852.
   PubMed Web of Science ®Google Scholar
• Gollob JA, Sciambi CJ, Peterson BL, et al. Phase I trial of sequential low-dose 5-aza-2ʹ-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2006 Aug 1;12(15):4619–4627. PubMed PMID: 16899610.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Desai JR, Issa JP, et al. A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs. 2014 Oct;32(5):969–975. PubMed PMID: 24875133.
   PubMed Web of Science ®Google Scholar
• Xia C, Leon-Ferre R, Laux D, et al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol. 2014 Oct;74(4):691–697. PubMed PMID: 25062770.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2006 Jan;18(1):77–82. PubMed PMID: 16357568.
   PubMed Web of Science ®Google Scholar
• Hong DS, Bowles DW, Falchook GS, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 1;18(15):4173–4182. PubMed PMID: 22693357.
   PubMed Web of Science ®Google Scholar
• van der Hiel B, Haanen JBAG, Stokkel MPM, et al. Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. BMC Cancer. 2017 Sep 15;17(1):649. PubMed PMID: 28915798.
   PubMedGoogle Scholar
• Queirolo P, Spagnolo F, Picasso V, et al. Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. Oncotarget. 2016 Jul 13;9(15):12408–12417. PubMed PMID: 29552321.
   PubMedGoogle Scholar
• Mooradian MJ, Reuben A, Prieto PA, et al. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 2018 Feb 1;7(5):e1423172. PubMed PMID: 29721378.
   PubMed Web of Science ®Google Scholar
• Addeo R, Zappavigna S, Luce A, et al. Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opin Drug Saf. 2013 Sep;12(5):729–740. PubMed PMID: 23560594.
   PubMed Web of Science ®Google Scholar
• Maccalli C, Giannarelli D, Capocefalo F, et al. Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. Oncoimmunology. 2015 Aug 12;5(2):e1071007. PubMed PMID: 27057436.
   PubMed Web of Science ®Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 Oct;19(10):1315-1327. PubMed PMID: 30219628.
   Web of Science ®Google Scholar
• Fujimura T, Kambayashi Y, Fujisawa Y, et al. Tumor-associated macrophages: therapeutic targets for skin cancer. Front Oncol. 2018 Jan 23;8:3. PubMed PMID:29410946.
   PubMed Web of Science ®Google Scholar